sunvozertinib
dizal pharmaceuticals
['sunvozertinib', 'lcsm,(-blcsm)']
sunvozertinib in egfr exon20ins with promising activity (wu-kong6 trial). post chemo, 60.8% orr in an interesting wf plot. even the 3 patients with previous ami good responses. orr regardless of mut subtype. dot 7m, dor nr. once again, toxicity is the achilles heel. #asco23 #lcsm 
Husband, Father. Medical Oncologist and Researcher focused in Thoracic Oncology.  Views are my own. Member of @latenightonc - the best podcast in oncology!